<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67013">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01744639</url>
  </required_header>
  <id_info>
    <org_study_id>GAS 720-12/13-1</org_study_id>
    <nct_id>NCT01744639</nct_id>
  </id_info>
  <brief_title>Analysis of Body Composition in Patients With Hepatocellular Carcinoma in Radioablation</brief_title>
  <official_title>Analysis of Body Composition by Bioelectrical Impedance in Patients With Hepatocellular Carcinoma (HCC) Undergoing Treatment Radioablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</source>
  <oversight_info>
    <authority>Mexico: Secretaria de Salud</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Number of shows: 20 patients Track: A month with three visiting Intervention: Nutritional
      assessment including anthropometry, bioelectrical impedance, biochemical tests, Psychometric
      Hepatic Encephalopathy Score and Critical Flicker Frequency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There will be a prospective, longitudinal, comparative. It included 20 patients diagnosed
      with hepatocellular carcinoma. As there are a finite number of active patients at the
      institute, and no studies with sample size well established, has seen a sample size of 20
      patients.

      The duration of individual monitoring shall be one month to three visits (baseline, week 2
      and week 4 after receiving the first radiofrequency ablation). Each visit will be a
      nutritional assessment including anthropometry, bioelectrical impedance, biochemical tests,
      Psychometric Hepatic Encephalopathy Score (PHES) and Critical Flicker Frequency (CFF).

      Anthropometric measures to be taken are weight, height and arm circumference average.

      Bioelectrical impedance will be using a single frequency impedance meter (425 to -50 KHz,
      Range 0 to 10,000) Bioelectrical Body Composition Analyzer Quantium II RJL Systems. The team
      measured the subjects' impedance, resistance, reactance and phase angle by Lean Body program
      provided by the manufacturer.

      Hepatic encephalopathy be evaluated by testing PHES and was measured CFF, also also be
      measured ammonium, tumor necrosis factor, IL-1, IL-6, IL-10, renin angiotensin aldosterone.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Nutritional Status</measure>
    <time_frame>Participants will be evaluated for a month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured with the following parameters:body weight and height (to calculate BMI), triceps skinfold and mid-arm circumference (to calculated mid-arm muscle circumference, fat mass, fat free mass total, intracellular and extracellular body water obtained by bioelectrical impedance analysis and individual vectors obtained by bioelectrical impedance vector analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minimal hepatic encephalopathy</measure>
    <time_frame>Participants will be assessed for one month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed by psychometric Hepatic Encephalopathy (PHES) and Critical Flicker Frequency (CFF)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Liver Carcinoma</condition>
  <arm_group>
    <arm_group_label>HCC under treatment with radioablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assessment of nutritional status by anthropometry, bioelectrical impedance, blood sampling and application of psychometric hepatic encephalopathy score and critical flicker frequency, to assess the presence of hepatic encephalopathy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>HCC under treatment with radioablation</intervention_name>
    <description>The evaluation will take place over a period of 30 days.</description>
    <arm_group_label>HCC under treatment with radioablation</arm_group_label>
    <other_name>Anthropometry</other_name>
    <other_name>Bioelectrical impedance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a diagnosis of hepatocellular carcinoma, treatment-naive and who are
             referred to the radiology department for radioablation as first therapy.

          -  Outpatients.

          -  Willingness to participate in the project.

        Exclusion Criteria:

          -  Patients with hepato-renal diseases.

          -  Patients diagnosed with hepatocellular carcinoma undergoing chemoembolization
             treatment, or who have received more than one session radioablation.

          -  Patients with depression or psychiatric illnesses

          -  Patients who do not agree to participate in the project.

        Exclusion Criteria:

          -  incomplete Applied Tests

          -  disagreement of the person to perform any of the tests

          -  monitoring Breach

          -  Hospitalization or death after the first session radioablation.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aldo Torre Delgadillo, M.D. M.Sc</last_name>
    <role>Principal Investigator</role>
    <affiliation>INCMNSZ</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aldo Torre, M.D. M.Sc</last_name>
    <phone>54870900</phone>
    <phone_ext>2709</phone_ext>
    <email>detoal@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán</name>
      <address>
        <city>Mexico City</city>
        <state>D.f.</state>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aldo Torre Delgadillo, M.D. M.Sci</last_name>
      <phone>54870900</phone>
      <phone_ext>2709</phone_ext>
      <email>detoal@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Ariadna Karen Flores Balbuena, LN</last_name>
      <phone>54870900</phone>
      <phone_ext>2709</phone_ext>
      <email>nut.ariadnakaren@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Aldo Torre Delgadillo, MDMSci</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ariadna Karen Flores Balbuena, LN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 16, 2013</lastchanged_date>
  <firstreceived_date>December 5, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</investigator_affiliation>
    <investigator_full_name>ALDO TORRE DELGADILLO</investigator_full_name>
    <investigator_title>Investigador Principal</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Radioablation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
